|Bid||75.20 x 200|
|Ask||75.25 x 200|
|Day's range||74.46 - 76.43|
|52-week range||11.41 - 79.75|
|PE ratio (TTM)||N/A|
|Earnings date||27 Feb 2018 - 5 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||50.00|
Nektar's (NKTR) shares soar in a year's time on a robust pipeline including several study initiations, positive readouts and strategic collaborations.
Nektar (NKTR) impresses with a strong pipeline of early and late-stage candidates. The company makes a significant progress with its lead candidate, Onzeald, for advanced breast cancer in adults.
These two biotechs have promising new opioid drugs. But one appears to be the better pick for investors in the new year.
Nektar's (NKTR) shares soar in the year so far on a robust pipeline including several study initiations and strategic collaborations.
Bristol-Myers Squibb, Incyte, and Nektar Therapeutics could provide the biggest fireworks next year on the immunotherapy scene.
Nektar Therapeutics (NKTR) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.
Nektar Therapeutics' (NKTR) NKTR-181 has already received fast-track designation from the FDA (U.S. Food & Drug Administration).
Nektar Therapeutics (NKTR) plans to submit an NDA (New Drug Application) with the FDA (U.S. Food & Drug Administration) for late-stage chronic pain drug NKTR-118 by April 2018.
On November 16, 2017, the FDA's Antimicrobial Drugs Advisory Committee voted down the 14-day regimen and 28-day regimen of Nektar Therapeutics' ciprofloxacin DPI.
Nektar Therapeutics (NKTR) recognized $128 million of the $150 million upfront payment from Eli Lilly (LLY) related to the development of investigational drug NKTR-358.
After the collaboration with Eli Lilly for investigational drug NKTR-358, Nektar Therapeutics (NKTR) increased its 2017 revenue projections to $250 million–$255 million.
In 3Q17, Nektar Therapeutics (NKTR) reported revenues of $152.9 million, a YoY rise of 320.7%. The sudden spurt is mainly due to the upfront payment of $150 million from Eli Lilly.
Nektar's (NKTR) shares skyrocket in the year so far on a robust pipeline including several study initiations and strategic collaborations.
If you've been craving exposure to highflying small-cap names like Netktar Therapeutics and MKSI Instruments, you may be in luck.
If you notice a relative who can't stop grinning at the Thanksgiving dinner table, they're probably holding shares of these biotech stocks.